Our lead candidate, Pneumococcal Conjugate Vaccine for Paediatric, leverages the Inventprise proprietary Linker Conjugation Platform to result in a longer-lasting vaccine with more coverage and a better immune response.
Inventprise’s proprietary scalable conjugation technology based on the Hydrazide-PEG-Hydrazide (Hz-PEG-Hz) linker designed to create specific, highly immunogenic, and broad-spectrum conjugate vaccines.
Inventprise’s proprietary scalable conjugation technology based on the Hydrazied-PEG-Hydrazide (Hz-PEG-Hz) linker designed to create specific, highly immunogenic, and broad-spectrum conjugate vaccines.
READ MORE
Play Video
State-of-the-Art, Highly Automated Manufacturing with Capacity to Supply Global Demand.
Play Video
State-of-the-Art, Highly Automated Manufacturing with Capacity to Supply Global Demand
PRESS RELEASE New Inventprise Pneumococcal Vaccine Enters Phase 1/2 Clinical Evaluation The pneumococcal conjugate vaccine is designed to broaden protection against life-threatening childhood pneumonia and
Highly automated manufacturing facility is expected to provide lifesaving vaccines to low- and middle-income countries, with additional supply to meet global demand.